The University of Michigan Comprehensive Cancer Center (UMCCC) requests the sixth renewal of its core grant since the initial NCI award in 1988. Dr. Max Wicha, the founding Director of the Cancer Center, continues to serve as Director, supported by a strong, nationally recognized senior leadership team. The Center provides an organizational framework to promote interdisciplinary cancer research through the development of well-funded basic, clinical and prevention programs in cancer research and the development of shared core resources. The Cancer Center's 13 research programs include six basic research programs in Cancer Genetics, Cancer Cell Biology, Radiation Sciences, Molecular Imaging, Experimental Therapeutics and Tumor Immunology Host Response;five clinical research programs: Hematologic Malignancies/BMT, Breast, Prostate, Gl and Head and Neck cancers;and two prevention programs Biomedical and Sociobehavioral. Support is requested for a total of 18 shared core facilities, including 13 existing cores. Clinical Trials, Biostatistis, Tissue and Molecular Pathology, Tumor Imaging, Morphology, Flow Cytometry, Experimental Irradiation, Transgenic Mouse, Vector, Immune Monitoring, Genomics, Informatics, Health Communications and five new cores: Patient and Population Sciences, High Throughput Screening, Pharmacokinetics, Structural Biology and Xenograft. Funds are also requested for development, senior leadership, planning and evaluation and administration to support center goals. The UMCCC's 337 members have contributed many high impact discoveries over this grant period. The Cancer Center's mission of """"""""the conquest of cancer through innovation and collaboration"""""""" is further evidenced by the high degree of intra- (15.6%) and inter- (35.4%) programmatic publications published in this grant period. The UMCCC's success is underscored by its current ranking as #1 in NCI funding among all matrix cancer centers. The Medical Center has continued to make substantial commitments to the Cancer Center in space, financial support and designation of cancers as among its highest priorities for both clinical and research investment. The acquisition of the former Pfizer campus, now called North Campus Research Complex, represents an unparalleled opportunity for cancer discovery over the next grant period.

Public Health Relevance

The goals of the U of M Comprehensive Cancer Center are to foster research productivity, promote interaction and collaboration and optimize the institution's strengths and unique scientific opportunities to advance cancer prevention, diagnosis, treatment and survivorship.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA046592-26S3
Application #
8917486
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
1997-06-01
Project End
2017-05-31
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
26
Fiscal Year
2014
Total Cost
$310,728
Indirect Cost
$110,796
Name
University of Michigan Ann Arbor
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Mendiratta-Lala, Mishal; Gu, Everett; Owen, Dawn et al. (2018) Imaging Findings Within the First 12 Months of Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys 102:1063-1069
Cilliers, Cornelius; Menezes, Bruna; Nessler, Ian et al. (2018) Improved Tumor Penetration and Single-Cell Targeting of Antibody-Drug Conjugates Increases Anticancer Efficacy and Host Survival. Cancer Res 78:758-768
Lorenz, Daniel A; Vander Roest, Steve; Larsen, Martha J et al. (2018) Development and Implementation of an HTS-Compatible Assay for the Discovery of Selective Small-Molecule Ligands for Pre-microRNAs. SLAS Discov 23:47-54
Zhou, Bing; Hu, Jiantao; Xu, Fuming et al. (2018) Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression. J Med Chem 61:462-481
Cho, Chun-Seok; Park, Hwan-Woo; Ho, Allison et al. (2018) Lipotoxicity induces hepatic protein inclusions through TANK binding kinase 1-mediated p62/sequestosome 1 phosphorylation. Hepatology 68:1331-1346
Chockley, Peter J; Chen, Jun; Chen, Guoan et al. (2018) Epithelial-mesenchymal transition leads to NK cell-mediated metastasis-specific immunosurveillance in lung cancer. J Clin Invest 128:1384-1396
Hertz, Daniel L; Kidwell, Kelley M; Vangipuram, Kiran et al. (2018) Paclitaxel Plasma Concentration after the First Infusion Predicts Treatment-Limiting Peripheral Neuropathy. Clin Cancer Res 24:3602-3610
Parsels, Leslie A; Karnak, David; Parsels, Joshua D et al. (2018) PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP Inhibitors. Mol Cancer Res 16:222-232
Menghrajani, Kamal; Boonstra, Philip S; Mercer, Jessica A et al. (2018) Predictive models for splenic response to JAK-inhibitor therapy in patients with myelofibrosis. Leuk Lymphoma :1-7
Xiong, Xiufang; Liu, Xia; Li, Haomin et al. (2018) Ribosomal protein S27-like regulates autophagy via the ?-TrCP-DEPTOR-mTORC1 axis. Cell Death Dis 9:1131

Showing the most recent 10 out of 1493 publications